Physician profile
James D Webb
NPI 1083110449
$1,077.10
in general payments reported to CMS, 2019-2025
21 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $202 · 2023: $332 · 2024: $317 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $213.02 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $196.14 | 2022-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $152.63 | 2022-2024 | |
| Abbvie INC. | $105.04 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Dexcom, INC. | $65.78 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $45.13 | 2023 | |
| Glaxosmithkline, LLC. | $33.88 | 2023 | Arexvy, Shingrix |
| Medtronic, INC. | $26.76 | 2025 | Intellis Adaptivestim |
| Lilly USA, LLC | $25.86 | 2022-2023 | Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.38 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $22.96 | 2022 | |
| Daiichi Sankyo INC. | $21.42 | 2023 | Injectafer |
| Abbott Laboratories | $19.47 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $19.31 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $17.29 | 2023 | Gvoke Hypopen |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2022 | |
| W. L. Gore & Associates, INC. | $16.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.19 | 2022 | |
| Astellas Pharma US INC | $14.25 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2022 | |
| Sumitomo Pharma America, INC. | $11.76 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.